UNSPSC 51384615: Niprofazone

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C21H25N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0A995E1KA6, chemically known as 5-pyrazolone, 1-phenyl-2,3-dimethyl-4-(n-nicotinamidomethyl-n-isopropyl)amino- but generally known as niprofazone, which bears US NIH Compound Identifier 65619. European Medicines Agency schedules Niprofazone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09302MIG.

UNSPSC 51384615 Niprofazone, a Commodity code, nominally designates a single pharmaceutical product, but recent state and local solicitations under this code show minimal direct purchasing of the named compound itself. Instead, the code appears misapplied or underutilized in state and local procurement activity; the recent opportunities tagged to it involve broader pharmaceutical procurement — naloxone distribution for harm reduction, generic multi-source pharmaceutical sourcing for cooperative purchasing, and exploratory vendor outreach for direct-to-manufacturer prescription programs. State and local health departments, cooperative purchasing alliances, and human services commissions are the active issuing bodies. The work spans emergency medical supplies (naloxone), generic pharmaceutical contracting through authorized wholesalers, and emerging direct-distribution models that circumvent traditional pharmacy benefit managers and group purchasing organizations.

Geographic activity is limited to Florida, Texas, and Minnesota in the recent record. Seminole County, Florida issued IFB 60459723LAS in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries and a response deadline of July 26, 2023 (note: date inconsistency in source). The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with awards effective July 1, 2026 across Minnesota and Oregon. The MMCAP procurement requires vendor relationships with AmerisourceBergen (Cencora), Cardinal Health, or Morris & Dickson as authorized wholesalers and carries a 3 percent administrative fee and $5 million commercial general liability insurance requirement.